{"id":"positive-control-vaccine-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a positive control vaccine, this agent is formulated to reliably trigger both humoral and cellular immune responses, serving as a reference standard in clinical trials. Positive control vaccines are used to validate trial methodology and demonstrate that the study population is capable of mounting appropriate immune responses. The specific antigenic composition and delivery mechanism are not publicly detailed.","oneSentence":"A positive control vaccine designed to elicit immune responses by presenting antigenic material to stimulate adaptive immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:29:42.361Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Positive control comparator in phase 3 clinical trials (specific indication not disclosed)"}]},"trialDetails":[{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT06692907","phase":"PHASE2","title":"Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-31","conditions":"Escherichia Infection","enrollment":72},{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":"Gonorrhea Male","enrollment":65},{"nctId":"NCT07395739","phase":"PHASE1","title":"A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks)","startDate":"2026-02-24","conditions":"Neisseria Meningitidis Serogroup B","enrollment":30},{"nctId":"NCT06183216","phase":"PHASE1","title":"A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2024-01-04","conditions":"Pneumococcal Infectious Disease","enrollment":140},{"nctId":"NCT07211152","phase":"PHASE3","title":"Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-10-13","conditions":"Influenza","enrollment":150},{"nctId":"NCT05092386","phase":"PHASE1","title":"Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-01-03","conditions":"Pneumococcal Infections","enrollment":310},{"nctId":"NCT04327440","phase":"","title":"RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi","status":"COMPLETED","sponsor":"Michigan State University","startDate":"2020-02-04","conditions":"Malaria, Malaria Vaccine, Insecticide-treated Bednets","enrollment":1691},{"nctId":"NCT06932523","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2025-04-04","conditions":"Herpes Zoster (HZ)","enrollment":645},{"nctId":"NCT07324356","phase":"NA","title":"Effects of Individual and Group Education on Mothers' Attitudes and Decisions About Childhood Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul University - Cerrahpasa","startDate":"2025-11-15","conditions":"Childhood Immunization","enrollment":75},{"nctId":"NCT07285265","phase":"PHASE1","title":"Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","startDate":"2025-05-27","conditions":"Varicella-zoster Virus","enrollment":180},{"nctId":"NCT06855836","phase":"NA","title":"Motivational Interviewing to Increase Uptake of Drug Checking and Safe Drug Use Behaviors to Reduce Overdose","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-03-03","conditions":"Overdose","enrollment":588},{"nctId":"NCT04083950","phase":"EARLY_PHASE1","title":"Induction of Gut Permeability by an Oral Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"USDA, Western Human Nutrition Research Center","startDate":"2019-12-04","conditions":"Intestinal Permeability, Inflammation, Vaccine","enrollment":10},{"nctId":"NCT06824519","phase":"PHASE1, PHASE2","title":"Clinical Trials of Quadrivalent Influenza Vaccine","status":"RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2025-05-08","conditions":"Influenza, Human","enrollment":620},{"nctId":"NCT03376477","phase":"PHASE2","title":"Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-09-23","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT06243666","phase":"","title":"Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiamen University","startDate":"2024-02-20","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Persistent Infection","enrollment":2188},{"nctId":"NCT06577298","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-12-19","conditions":"Poliomyelitis","enrollment":480},{"nctId":"NCT07035054","phase":"PHASE2","title":"Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2024-04-20","conditions":"Streptococcus Pneumoniae Pneumonia","enrollment":992},{"nctId":"NCT07025876","phase":"EARLY_PHASE1","title":"PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2023-11-18","conditions":"Streptococcus Pneumoniae Pneumonia","enrollment":240},{"nctId":"NCT06714513","phase":"PHASE1","title":"ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74","status":"RECRUITING","sponsor":"Quratis Inc.","startDate":"2025-05-09","conditions":"Tuberculosis, Pulmonary","enrollment":144},{"nctId":"NCT06843317","phase":"PHASE1","title":"Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults","status":"RECRUITING","sponsor":"Clover Biopharmaceuticals USA, LLC","startDate":"2025-03-21","conditions":"RSV Infection","enrollment":160},{"nctId":"NCT04078269","phase":"PHASE1","title":"MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2019-08-26","conditions":"Non-small Cell Lung Cancer","enrollment":6},{"nctId":"NCT06306196","phase":"PHASE2","title":"Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children","status":"RECRUITING","sponsor":"International Vaccine Institute","startDate":"2024-04-04","conditions":"Hepatitis E Virus Infection","enrollment":1040},{"nctId":"NCT06131554","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-20","conditions":"Meningococcal Meningitis","enrollment":1480},{"nctId":"NCT05691790","phase":"NA","title":"Older People's Preventive Care Utilization","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2024-10-01","conditions":"Health Communication","enrollment":270},{"nctId":"NCT05951725","phase":"PHASE3","title":"A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-08-11","conditions":"Diphtheria, Tetanus and Acellular Pertussis","enrollment":2520},{"nctId":"NCT06442241","phase":"PHASE1","title":"A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2024-07-31","conditions":"Respiratory Syncytial Virus (RSV), RSV Infection","enrollment":84},{"nctId":"NCT06335849","phase":"PHASE1","title":"A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2024-03-27","conditions":"Herpes Zoster","enrollment":48},{"nctId":"NCT06851832","phase":"PHASE1, PHASE2","title":"Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older","status":"RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-02-16","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":960},{"nctId":"NCT06800950","phase":"PHASE3","title":"Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-02-08","conditions":"Influenza, Human, Influenza, Human Prevention, Influenza a","enrollment":4400},{"nctId":"NCT06622590","phase":"PHASE1","title":"Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2024-10-13","conditions":"Influenza, Human, Influenza a, Influenza Type B","enrollment":180},{"nctId":"NCT06752174","phase":"PHASE3","title":"A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2023-03-08","conditions":"Poliomyelitis","enrollment":300},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":"Malaria","enrollment":301},{"nctId":"NCT06101173","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2024-01-15","conditions":"Poliomyelitis","enrollment":72},{"nctId":"NCT05622942","phase":"PHASE1","title":"Clinical Trial of Recombinant Pneumococcal Protein Vaccine","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-03-11","conditions":"Pneumonia, Respiratory Tract Diseases, Respiratory Tract Infections","enrollment":60},{"nctId":"NCT06120751","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-20","conditions":"Tetanus","enrollment":1000},{"nctId":"NCT06123663","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-12-20","conditions":"Tetanus","enrollment":60},{"nctId":"NCT02938442","phase":"PHASE1, PHASE2","title":"Vaccination of Triple Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2019-01-25","conditions":"Triple Negative Breast Cancer, Breast Neoplasms","enrollment":16},{"nctId":"NCT05978037","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-08-18","conditions":"Malaria, Malaria,Falciparum, Parasitic Disease","enrollment":58},{"nctId":"NCT05216510","phase":"PHASE1","title":"Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens","status":"TERMINATED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2022-01-07","conditions":"Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2","enrollment":9},{"nctId":"NCT06662071","phase":"","title":"A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid Technology","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-10-01","conditions":"Bladder Cancer","enrollment":293},{"nctId":"NCT05178901","phase":"PHASE1","title":"A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Public Health Vaccines LLC","startDate":"2022-01-10","conditions":"Nipah Virus Infection","enrollment":60},{"nctId":"NCT05808166","phase":"PHASE2","title":"Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women","status":"RECRUITING","sponsor":"International Vaccine Institute","startDate":"2024-05-02","conditions":"Hepatitis E Infection","enrollment":2358},{"nctId":"NCT05208060","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells","status":"UNKNOWN","sponsor":"Inmunotek S.L.","startDate":"2023-09-01","conditions":"Immune Response","enrollment":48},{"nctId":"NCT03926728","phase":"PHASE1","title":"Safety and Immunogenicity of a Chlamydia Vaccine CTH522","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2020-02-17","conditions":"Trachoma","enrollment":65},{"nctId":"NCT06548139","phase":"PHASE2","title":"Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2024-07-31","conditions":"Rabies Virus Infection","enrollment":120},{"nctId":"NCT05574985","phase":"NA","title":"Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2022-08-29","conditions":"COVID-19","enrollment":272},{"nctId":"NCT04661579","phase":"PHASE2","title":"Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy","status":"COMPLETED","sponsor":"PATH","startDate":"2020-11-06","conditions":"Plasmodium Falciparum","enrollment":620},{"nctId":"NCT05545371","phase":"PHASE3","title":"Prevention of Rabies With Four Doses of Rabies Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Changchun Zhuoyi Biological Co., Ltd","startDate":"2022-06-18","conditions":"Rabies Human, Antibody","enrollment":2100},{"nctId":"NCT06424002","phase":"PHASE4","title":"The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children","status":"NOT_YET_RECRUITING","sponsor":"Kamuzu University of Health Sciences","startDate":"2024-06-01","conditions":"Malaria,Falciparum","enrollment":5400},{"nctId":"NCT05208125","phase":"PHASE1","title":"A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals","status":"COMPLETED","sponsor":"IrsiCaixa","startDate":"2022-03-30","conditions":"HIV Infection","enrollment":30},{"nctId":"NCT05282017","phase":"","title":"LatInamerican Vaccine Effectiveness Against Hospitalizations Due to Circulating COVID-19 VoC RWE Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-02-01","conditions":"COVID-19, SARS-CoV-2","enrollment":792},{"nctId":"NCT05252715","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-12-18","conditions":"Meningitis, Meningococcal","enrollment":1200},{"nctId":"NCT06314659","phase":"PHASE3","title":"Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-09-17","conditions":"Healthy Population","enrollment":630},{"nctId":"NCT06344065","phase":"PHASE3","title":"Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants","status":"RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-12-21","conditions":"Healthy Volunteers","enrollment":1584},{"nctId":"NCT06314685","phase":"PHASE3","title":"Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-12-10","conditions":"Healthy Population","enrollment":2450},{"nctId":"NCT04841369","phase":"PHASE3","title":"Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2021-04-13","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":3420},{"nctId":"NCT01979406","phase":"PHASE1","title":"A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2013-11","conditions":"Anthrax Infection","enrollment":120},{"nctId":"NCT06196502","phase":"NA","title":"The Effect of Gentle Human Touch and Kangaroo Care on Pain and Crying Physiological Parameters During Hepatitis-B Vaccination in a Newborn","status":"UNKNOWN","sponsor":"Kirsehir Ahi Evran Universitesi","startDate":"2024-02-01","conditions":"Pain","enrollment":80},{"nctId":"NCT05284812","phase":"PHASE2","title":"A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)","status":"SUSPENDED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2022-02-10","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT05939648","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2023-10-09","conditions":"SARS-CoV-2","enrollment":450},{"nctId":"NCT05663086","phase":"PHASE2","title":"Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above","status":"WITHDRAWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2023-01-07","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05477693","phase":"PHASE4","title":"Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-10-25","conditions":"Pneumococcal Infections","enrollment":1800},{"nctId":"NCT05475704","phase":"","title":"Effectiveness of Chinese COVID-19 Vaccines in Latin America and the Caribbean","status":"COMPLETED","sponsor":"P95","startDate":"2022-05-23","conditions":"COVID-19","enrollment":59},{"nctId":"NCT04364035","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients","status":"COMPLETED","sponsor":"Aelix Therapeutics","startDate":"2020-02-20","conditions":"HIV/AIDS","enrollment":50},{"nctId":"NCT05832073","phase":"EARLY_PHASE1","title":"Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1","status":"UNKNOWN","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2023-04-30","conditions":"Rabies Virus Infection","enrollment":152},{"nctId":"NCT05323461","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-05-30","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":1800},{"nctId":"NCT05552573","phase":"PHASE1","title":"Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above","status":"UNKNOWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2022-07-19","conditions":"COVID-19","enrollment":100},{"nctId":"NCT02933281","phase":"PHASE1, PHASE2","title":"MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa","status":"COMPLETED","sponsor":"International AIDS Vaccine Initiative","startDate":"2018-05-14","conditions":"Tuberculosis","enrollment":144},{"nctId":"NCT05722106","phase":"NA","title":"Improving Adherence to COVID-19 Prevention Behaviours: Test of Persuasive Messages","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2021-03-03","conditions":"COVID-19","enrollment":3746},{"nctId":"NCT05217563","phase":"NA","title":"Reframing Needle-related Pain","status":"TERMINATED","sponsor":"University of Calgary","startDate":"2022-02-01","conditions":"Pain, Procedural","enrollment":77},{"nctId":"NCT05683561","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2023-01-25","conditions":"COVID-19 SARS-CoV-2 Infection","enrollment":6000},{"nctId":"NCT05518760","phase":"","title":"COVID-19 Effectiveness Study in the Philippines","status":"UNKNOWN","sponsor":"University of the Philippines","startDate":"2022-11-09","conditions":"COVID-19, Vaccine Effectiveness Against COVID-19, Hospitalized COVID-19","enrollment":3000},{"nctId":"NCT04100772","phase":"PHASE1","title":"Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2020-05-18","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":237},{"nctId":"NCT04099303","phase":"PHASE1","title":"Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2020-04-28","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":400},{"nctId":"NCT04001322","phase":"NA","title":"Tunatar da ni. The Immunization Reminder and Information SMS System (IRISS)","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2019-06-15","conditions":"Low Immunization Uptake","enrollment":21},{"nctId":"NCT05150496","phase":"PHASE2","title":"Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey","status":"SUSPENDED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-12-15","conditions":"COVID-19","enrollment":640},{"nctId":"NCT04810117","phase":"","title":"Monitoring the IgG/IgM Antibodies in COVID-19 Patients","status":"COMPLETED","sponsor":"University of Sargodha","startDate":"2021-06-15","conditions":"COVID-19 Infections","enrollment":373},{"nctId":"NCT03947775","phase":"PHASE2","title":"HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2022-09-01","conditions":"Anal Intraepithelial Neoplasia, Anal Cancer, Human Papilloma Virus","enrollment":228},{"nctId":"NCT04148118","phase":"PHASE1","title":"A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"BlueWillow Biologics","startDate":"2020-01-08","conditions":"Anthrax","enrollment":84},{"nctId":"NCT05345873","phase":"PHASE2","title":"A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-07-01","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":300},{"nctId":"NCT05329051","phase":"PHASE2","title":"A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-07-01","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":400},{"nctId":"NCT05238649","phase":"PHASE2","title":"Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine","status":"UNKNOWN","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2021-11-10","conditions":"COVID-19 Pandemic","enrollment":150},{"nctId":"NCT05284851","phase":"PHASE2","title":"The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine","status":"UNKNOWN","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2022-04-01","conditions":"Influenza Prevention","enrollment":2520},{"nctId":"NCT02564523","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-11-06","conditions":"Hemorrhagic Fever, Ebola","enrollment":1075},{"nctId":"NCT05238454","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-03-20","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":600},{"nctId":"NCT04533399","phase":"PHASE2","title":"A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2020-08-17","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":4422},{"nctId":"NCT05244356","phase":"NA","title":"Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation","status":"COMPLETED","sponsor":"Clinical Research Centre, Malaysia","startDate":"2021-04-29","conditions":"COVID-19, Respiratory Disease, Vaccine Refusal","enrollment":5784},{"nctId":"NCT01312389","phase":"PHASE1, PHASE2","title":"A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"TERMINATED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2011-04","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":3},{"nctId":"NCT00000896","phase":"NA","title":"A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT05060484","phase":"PHASE2","title":"A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2021-10-19","conditions":"Interventional, Prevention, Randomized","enrollment":1800},{"nctId":"NCT04894448","phase":"","title":"Immunogenicity of COVID-19 Vaccination in PLWH","status":"UNKNOWN","sponsor":"CIHR Canadian HIV Trials Network","startDate":"2021-06-10","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT04391647","phase":"","title":"Developing Methods to Investigate Additional Opportunities of HPV Vaccination by Using First-void Urine Samples","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2020-05-11","conditions":"Human Papilloma Virus Infection","enrollment":50},{"nctId":"NCT03827395","phase":"PHASE1","title":"Safety Study of Hepatitis E Vaccine (HEV239)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-12","conditions":"Hepatitis E, Immunisation","enrollment":25},{"nctId":"NCT04921111","phase":"PHASE1","title":"A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2021-07-02","conditions":"HPV Infection Vaccine Safety SCT1000","enrollment":240},{"nctId":"NCT03491553","phase":"PHASE2","title":"Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-04-06","conditions":"Chronic Hepatitis B","enrollment":48},{"nctId":"NCT04075201","phase":"PHASE1","title":"Clinical Trial of Recombinant Hepatitis B Vaccine (Hansenula Polymorpha, 10μg)","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2019-07-07","conditions":"Hepatitis B","enrollment":144},{"nctId":"NCT01540474","phase":"PHASE1","title":"Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2012-02","conditions":"Malaria","enrollment":36},{"nctId":"NCT04082182","phase":"PHASE1","title":"MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"University Hospital, Ghent","startDate":"2019-08-26","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":7},{"nctId":"NCT04648800","phase":"PHASE3","title":"Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland","status":"UNKNOWN","sponsor":"Hanna Czajka","startDate":"2020-07-07","conditions":"Covid19, BCG Vaccination Reaction, SARS-CoV Infection","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Positive control vaccine 1","genericName":"Positive control vaccine 1","companyName":"Jiangsu Province Centers for Disease Control and Prevention","companyId":"jiangsu-province-centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"A positive control vaccine designed to elicit immune responses by presenting antigenic material to stimulate adaptive immunity. Used for Positive control comparator in phase 3 clinical trials (specific indication not disclosed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}